Changes in Beneficial Ownership · 4
NovaBridge Biosciences
Changes in Beneficial Ownership
Structured filing — 4
form4-09212026_040901.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- NovaBridge Biosciences
- Issuer CIK
- 0001778016
- Trading symbol
- NBP
Reporting owner 1
- Name
- Dennis Phillip Andrew
- Reporting owner CIK
- 0002089237
- Relationship
- Officer
- Officer title
- Chief Medical Officer
- Address
- C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE, MD, 20850
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares[F1] | 2026-09-17 | M · Form 4 | 23,695[F2] | A | [F3] | 181,636[F4] | D |
| Ordinary Shares[F1] | 2026-09-18 | S · Form 4 | 8,209[F5] | D | 0.71[F6] | 173,427[F7] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share Units | [F3] | 2026-09-17 | M · Form 4 | 10,302[F8] | D | 0 | [F9] | [F9] | Ordinary Shares[F1] | 10,302[F8] | 72,120[F8] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.↩ 1↩ 2↩ 3
- F2
- Reported securities are represented by 10,302 ADSs.↩ 1
- F4
- Reported securities are represented by 78,972 ADSs.↩ 1
- F5
- Reported securities are represented by 3,569 ADSs.↩ 1
- F6
- Reported sales price represents the converted sales price of the ADSs of $1.6247.↩ 1
- F7
- Reported securities are represented by 75,403 ADSs.↩ 1
Signature 1
- Signed
- /s/ Kyler Lei, Attorney-in-Fact
- Date
- 2026-09-21
Company context
NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.